Sorafenib plus Hycamtin Combo Prolongs Survival in Platinum-resistant Ovarian Cancer, Phase 2 Trial Shows

Sorafenib plus Hycamtin Combo Prolongs Survival in Platinum-resistant Ovarian Cancer, Phase 2 Trial Shows
Adding sorafenib, an anti-cancer oral medicine, to Hycamtin (topotecan) chemotherapy slows the time to disease progression or death in women with platinum-resistant ovarian cancer, a Phase 2 trial shows. The trial showed that the combo therapy prolonged median progression-free survival almost seven months, compared to Hycamtin alone. The study, “Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial,” was published in the journal The Lancet Oncology. Sorafenib (produced by Bayer under the brand name Nexavar) is a U.S. Food and Drug Administration (FDA)-approved oral treatment for liver, kidney, and thyroid cancer. The compound is an antiangiogenic agent, one that inhibits blood vessels' growth, reducing blood flow to the tumor and blocking tumor cell proliferation. Similarly to other classes of antiangiogenic agents, once-daily sorafenib showed anti-tumor activity in preclinical models of ovarian cancer. However, to date, clinical trials testing the therapy revealed only a moderate efficacy, either alone or in combination with chemotherapy. Novartis' Hycamtin is a chemotherapy approved in the United States and Europe for advanced ovarian cancer. Its efficacy was seen to parallel other chemotherapies, including paclitaxel or pegylated liposomal doxorubicin (PLD), for platinum-resistant ovarian cancer; and a conventional 5-day treatment was proven as effective as a weekly schedule. Based on such knowledge, researchers conducted the TRIAS Phase 2 study (NCT01047891) to assess the safety and efficacy of a combo treatment with 5-day Hycamtin plus oral sorafenib, followed by sorafenib alone as a maintenance therapy, in women who fai
Subscribe or to access all post and page content.